Mineralys Therapeutics
MLYS
67 hedge funds and large institutions have $385M invested in Mineralys Therapeutics in 2023 Q1 according to their latest regulatory filings, with 67 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
60.24% more ownership
Funds ownership: 0% → 60.24% (+60%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$76.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$53.5M |
| 3 |
ASP
Adams Street Partners
Chicago,
Illinois
|
+$40.7M |
| 4 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
+$30.2M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$21.3M |
Top Sellers
MLYS Hedge Fund Activity: Q1 2023 in Review
67 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Mineralys Therapeutics (MLYS) for Q1 2023, worth a combined $385M.
Buyers outnumbered sellers: 67 funds opened new MLYS positions and 0 closed out — a net gain of 67 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Samsara BioCapital, opening a new position worth an estimated $76.1M.
- 67 institutional investors held Mineralys Therapeutics (MLYS) as of Q1 2023, up from 0 in Q4 2022.
- Funds reported $385M of Mineralys Therapeutics stock for Q1 2023.
- 67 funds opened new Mineralys Therapeutics positions in Q1 2023 and 0 closed out, a net change of +67 holders.
- The largest Mineralys Therapeutics buyer in Q1 2023 was Samsara BioCapital, an estimated $76.1M added.
Based on aggregated 13F filings for Q1 2023.